Evidence map›Paper›PMID 41699646›Full record

ArticleJournal of ovarian research2026

HuMSCs-derived exosomes alleviate premature ovarian insufficiency by enhancing SIRT3-mediated mitochondrial function in theca-interstitial cells.

Xiangrong Cui, Xinyu Zhu, Jiali Luo, Ruixiang Zhu, Ruotong Ju, Puhua Zhang, Huihui Li, Shu Wang, Li Peng, Chenyu Jia and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiangrong CuiShanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Xinyu ZhuClinical Laboratory, Shanxi Provincial People's Hospital (Fifth Hospital) of Shanxi Medical University, Taiyuan, 030001, China.
Jiali LuoClinical Laboratory, Shanxi Provincial People's Hospital (Fifth Hospital) of Shanxi Medical University, Taiyuan, 030001, China.
Ruixiang ZhuClinical Laboratory, Shanxi Provincial People's Hospital (Fifth Hospital) of Shanxi Medical University, Taiyuan, 030001, China.
Ruotong JuReproductive Medicine Center, The affiliated Children's Hospital of Shanxi Medical University, Children's Hospital of Shanxi, Shanxi Maternal and Child Health Hospital, Taiyuan, 030001, China.
Puhua ZhangReproductive Medicine Center, The affiliated Children's Hospital of Shanxi Medical University, Children's Hospital of Shanxi, Shanxi Maternal and Child Health Hospital, Taiyuan, 030001, China.
Huihui LiReproductive Medicine Center, The affiliated Children's Hospital of Shanxi Medical University, Children's Hospital of Shanxi, Shanxi Maternal and Child Health Hospital, Taiyuan, 030001, China.
Shu WangReproductive Medicine Center, The affiliated Children's Hospital of Shanxi Medical University, Children's Hospital of Shanxi, Shanxi Maternal and Child Health Hospital, Taiyuan, 030001, China.
Li PengShanxi Hospital of Integrated Traditional and Western Medicine of Shanxi University of Traditional Chinese Medicine, Taiyuan, 030000, Shanxi, China.
Chenyu JiaReproductive Medicine Center, The affiliated Children's Hospital of Shanxi Medical University, Children's Hospital of Shanxi, Shanxi Maternal and Child Health Hospital, Taiyuan, 030001, China.
Tingting XueShanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Xuan JingClinical Laboratory, Shanxi Provincial People's Hospital (Fifth Hospital) of Shanxi Medical University, Taiyuan, 030001, China. jx05070103@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Premature ovarian insufficiency (POI) is a reproductive disorder lacking effective treatment options. This study explores the therapeutic potential of exosomes derived from human umbilical cord mesenchymal stem cells (HuMSCs-Exos) in restoring ovarian function in a cyclophosphamide (CTX)-induced POI mouse model. HuMSCs-Exos treatment significantly improved ovarian structure, restored follicular development, and normalized key hormone levels, enhancing estrous cycle regularity and fertility in POI mice. Mechanistic investigations revealed that HuMSCs-Exos promote SIRT3 expression, which modulates mitochondrial dynamics and reduces apoptosis in ovarian theca-interstitial cells (TICs). Furthermore, HuMSCs-Exos restored mitochondrial membrane potential and enhanced testosterone synthesis in TICs under CTX-induced stress, effects that were mitigated by the SIRT3 inhibitor 3-TYP, highlighting SIRT3 as a critical mediator. These findings indicate that HuMSCs-Exos support ovarian recovery, with effects consistent with the activation of SIRT3-mediated mitochondrial stabilization pathways in TICs, suggesting a promising therapeutic approach for POI.

Indexed as

ExosomesMesenchymal Stem CellsMitochondriaPrimary Ovarian InsufficiencySirtuin 3Theca CellsAnimalsApoptosisDisease Models, AnimalFemaleHumansMiceSirt3 protein, mouseSirtuin 3HuMSCs-ExosMitochondrial dynamicsPremature ovarian insufficiency (POI)SIRT3Theca-interstitial cells

Identifiers

PMID41699646
PMCPMC13014851

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.